Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ
Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ
Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer.
在首次拜訪Grail Inc. (納斯達克：GRAL)將近四年後，Illumina Inc. (納斯達克：ILMN)於週一宣佈將分拆該癌症血液檢測開發商。
In July 2021, Illumina said it was committed to re-acquiring Grail.
2021年7月，Illumina表示致力於收購Grail。
Starting today, 25 June, Grail will begin trading the "regular way" under its own Nasdaq ticker, GRAL, as an independent public firm.
從6月25日起，Grail將以其自己的Nasdaq股票代碼GRAL作爲獨立的上市公司進行“常規方式”交易。
Earlier this month, Illumina laid out its plans for the Grail spin-off and said its shareholders will retain their current shares of Illumina common stock and, on the distribution date, also receive one share of GRAIL common stock for every six shares of Illumina common stock.
本月早些時候，Illumina公佈了其Grail分拆計劃，並表示其股東將保留其當前的Illumina普通股份，並在發行日收到每六股Illumina普通股份換取一股GRAIL普通股份。
Illumina will maintain a 14.5% share of the company.
Illumina將持有該公司14.5%的股份。
As previously disclosed, Illumina entered into a 364-day delayed draw credit agreement that provided for a senior unsecured term loan credit facility in an aggregate principal amount of up to $750 million at a borrowing rate of approximately 6.70%.
正如此前披露的，Illumina簽訂了一項364天的滯後抽取信貸協議，提供一個高達7.5億美元的優先無擔保期限貸款額度，借款利率約爲6.70%。
In December, Illumina agreed to divest Grail as the companies battled with the U.S. and European antitrust regulators for almost three years after announcing the acquisition.
去年12月，Illumina同意出售Grail，因爲在宣佈收購後的三年裏，該公司與美國和歐洲的反壟斷監管機構展開了鬥爭。
In March, an adviser to Europe's top court criticized the decision to block Illumina's $7.1 billion bid for Grail, stating that they exceeded their powers.
今年3月，歐洲最高法院的一名顧問批評了阻止Illumina以71億美元收購Grail的決定，並稱他們超越了其權限。
Last year, in July, the European Commission fined Illumina approximately $463 million (432 million euros), and Grail $1,072 (1,000 euros) for implementing their proposed merger before approval by the commission, in breach of EU merger control rules.
去年7月，歐洲委員會對Illumina處以大約4.63億美元（4.32億歐元）的罰款，對Grail處以1,072歐元（1,000歐元）的罰款，原因是在未獲批准的情況下實施了他們的擬議合併，違反了歐盟的併購控制規則。
"As we turn the page, we are excited to share our plan to accelerate topline growth, achieve operational excellence, deliver for our customers, and maximize value for shareholders in our upcoming strategy update," said Jacob Thaysen, CEO of Illumina.
Illumina的首席執行官雅各布•塔伊森（Jacob Thaysen）表示：“當我們翻開新的一章時，我們很高興能夠分享我們的計劃，即在未來的戰略更新中加速營收增長、實現運營卓越、爲客戶提供服務並最大化股東價值。”
"Illumina is prepared to lead the next era of innovation in next-generation sequencing by continuing to focus on strengthening our business and catalyzing the industry with an even greater focus on our customers' priorities."
“Illumina準備通過繼續專注於強化我們的業務，並更加關注客戶的優先事項，來引領下一代測序創新的下一個時代。”
Grail CEO Bob Ragusa told Reuters that Grail's cancer blood test, Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for, which results in cancer deaths.
Grail首席執行官鮑勃·雷古薩告訴路透社，Grail的癌症血液檢測產品Galleri可以早期檢測多種類型的癌症，並針對目前未被篩查的80%的癌症，從而達到預防癌症死亡的效果。
Reuters noted the company is conducting two major clinical trials, one in the U.K., to support an FDA approval application in early 2026. If approved in the U.S., the test could be widely used.
路透社指出，該公司正在進行兩項重大的臨床試驗，其中之一是在英國進行的，以支持在2026年初向美國食品和藥物管理局提交批准申請。如果在美國獲得批准，該檢測產品可能會被廣泛應用。
Price Action: ILMN shares closed at $110.24 on Monday.
價格行情：ILMN股票週一收於110.24美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。